# Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer

> **NCT00042952** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 32 (actual)

## Conditions studied

- Ovarian Dysgerminoma
- Recurrent Malignant Testicular Germ Cell Tumor
- Recurrent Ovarian Germ Cell Tumor
- Stage II Malignant Testicular Germ Cell Tumor
- Stage II Ovarian Germ Cell Tumor
- Stage III Malignant Testicular Germ Cell Tumor
- Stage III Ovarian Germ Cell Tumor
- Testicular Seminoma

## Interventions

- **DRUG:** imatinib mesylate
- **PROCEDURE:** therapeutic conventional surgery
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00042952
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2002-06
- **Primary completion:** 2003-10
- **Final completion:** —
- **Target enrollment:** 32 (ACTUAL)
- **Why stopped:** Administratively complete.
- **Last updated:** 2013-01-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00042952

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00042952, "Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00042952. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*